5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Aurobindo Pharma Ltd.

•
aurobindo.comBSE: 524804NSE: AUROPHARMA
Market Cap₹ 96,402 Cr.
Current Price
High / Low₹ 1,717 / 1,067
Stock P/E26.0
Book Value₹ 676
Price to Book2.00
Dividend Yield0.24 %
ROCE12.8 %
ROE9.9 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has consistently been profitable over the last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.17x)
  • Latest quarter profit grew 25.2% YoY, showing strong momentum
  • Company comfortably covers its interest (14.3x coverage)
  • Company generates healthy free cash flow
  • Company maintains a comfortable, low leverage position

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • Company has delivered a poor profit growth of -8.1% over past five years
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor sales growth of 6.3% over past five years
  • Though reporting repeated profits, the company pays out little dividend (6.6%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYM150MOMNTM50NIFTY PHARMANIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 100
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
6,7917,1517,2717,4927,4587,6467,8938,3817,7928,2378,6058,7529,150
5,6995,8465,7505,9075,9476,2306,4016,5906,2656,6086,8737,1017,858
Operating Profit1,0911,3051,5211,5851,5101,4161,4931,7911,5271,6291,7321,6511,293
OPM %16.07%18.25%20.91%21.15%20.25%18.52%18.91%21.37%19.59%19.78%20.13%18.86%14.13%
4718716314221136157135105121122117304
Interest5768768911111311811598959398102
Depreciation327418423354404382419444406429465479487
Profit before Tax8151,0751,2651,2431,3251,2071,1981,3671,2051,2741,3381,2931,515
Tax %29.74%30.12%25.49%25.96%30.61%32.35%29.57%31.61%31.75%33.57%32.04%28.60%31.88%
Net Profit00009188178469038248489109211,032
9.7412.8316.0415.5115.6914.0014.5615.5614.2014.6115.6715.8617.86

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
14,91016,46319,56423,09924,77523,45524,85529,00231,72433,65334,743
11,47512,69115,61218,23419,44119,07121,13723,15925,14126,83628,438
Operating Profit3,4343,7723,9524,8645,3334,3853,7195,8436,5836,8176,305
OPM %23.03%22.91%20.20%21.06%21.53%18.69%14.96%20.15%20.75%20.26%18.15%
116102671663,195195291366622455664
Interest67782633057449140290457384388
Depreciation4285586689671,0551,1271,2451,5221,6491,7781,859
Profit before Tax3,0613,2413,0913,7437,3443,3732,6124,3805,0665,1125,421
Tax %24.82%25.25%23.51%24.03%27.37%21.51%26.21%27.65%31.24%31.47%31.53%
Net Profit2,3012,4232,3642,8445,3342,6471,9283,1693,4843,5033,711
EPS39.3341.3640.3648.5691.0545.1932.9054.1660.0260.34—
Dividend Payout %6.36%6.04%6.19%6.18%4.39%19.91%9.12%8.31%0.00%6.63%—

COMPOUNDED SALES GROWTH

10 Years:
9%
5 Years:
6%
3 Years:
11%

COMPOUNDED PROFIT GROWTH

10 Years:
6%
5 Years:
-8%
3 Years:
22%

STOCK PRICE CAGR

10 Years:
8%
5 Years:
18%
3 Years:
24%
1 Year:
51%

RETURN ON EQUITY

10 Years:
17%
5 Years:
10%
3 Years:
11%
Last Year:
10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Apr 17

₹ 1475.00

Buy Back of Shares

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital59595959595959595858
Minority Interest2220-1-2128-6-8
9,31311,62213,83216,76621,87124,51726,78129,78432,59537,833
3,2734,7816,7875,7745,3322,7275,2126,5177,3407,954
Trade Payables2,1552,3732,5522,5762,7952,7033,8714,4544,1895,567
1,2802,1073,0403,5893,3463,6293,2773,0364,3175,615
Total Liabilities16,08220,94226,27128,76533,40133,63339,21243,85948,49257,019
4,8346,5218,4759,3969,37410,53211,02414,49314,79417,407
Capital Work in Progress1,2371,4001,3421,6222,4292,9384,4962,7393,2663,009
2463123605555919975433722521,051
4,3315,8587,2467,7009,0277,5548,5119,80810,54412,053
0151602716254,8175,7467,094
Cash & Bank5131,2621,9572,8425,4744,1906,0846,2788,2359,870
4,9215,5756,8756,6506,4807,4078,5295,3515,6556,534
Total Assets16,08220,94226,27128,76533,40133,63339,21243,85948,49257,019

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4,0522,6532,4215,1424,6146,2753,1042,4353,9255,526
Cash from Investing-1,787-1,927-2,903-1,568599-3,212-3,978-4,256-1,876-3,459
Cash from Financing-1,9158641,919-1,947-1,365-2,9691,814800120-1,269
-4248926678662,563-1,164223-1,0212,169799

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
51.8051.8251.8251.8251.8251.8251.8251.8251.88
16.7316.5916.2915.3314.3814.2113.9515.2416.38
24.7725.1425.2126.2326.9327.6027.6625.8225.05
Government0.000.000.000.000.000.000.000.000.00
6.706.466.696.616.876.386.567.086.64

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-12
Acquisition

2026-09-12 - Aurobindo Pharma Limited has informed the Exchange about Acquisition

2026-09-11
General Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Unit-IV of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Aurobindo Pharma Limited has informed the Exchange about Schedule of meet

2026-09-03
Copy of Newspaper Publication

2026-09-03 - Aurobindo Pharma Limited has submitted copy of Newspaper Publications.

2026-09-01
Acquisition

2026-09-01 - AUROPHARMA: Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned subsidiary by the name of Avogent Lifesciences Private Limited in India by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

News

Recent coverage and analyst commentary for AUROPHARMA

Loading news…

🤖

AI Stock Analyst

Aurobindo Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login